Navigation Links
Novavax Reports Fourth Quarter and 2008 Year-End Financial Results
Date:3/31/2009

li>
  • The Company took significant measures, including a reduction in force early this year, to reduce its expenses and thereby the yearly burn rate.

  • "We made significant progress in 2008 in advancing our VLP based vaccine pipeline. We demonstrated in Phase II clinical studies that our VLP based flu vaccines are not only well tolerated and immunogenic in humans, but they have the potential to differentiate themselves from currently available alternatives. We also demonstrated that our VLP technology has the potential to create a much needed vaccine against RSV. These advances continue to reinforce that our strategy of using the VLP vaccine platform coupled with our innovative manufacturing solution is working," said Novavax Chief Executive Officer Dr. Rahul Singhvi. "By the second half of 2009, we want to translate these scientific advances into partnerships with private and public entities to leverage capabilities of our partners to accelerate our progress, as we have shown today with the Cadila partnership."

    2008 Financial Results

    Revenue from continuing operations, for the fourth quarter ended December 31, 2008, related to the government contracts was $100,000 compared to $400,000 for the same period in 2007. Revenue for the full year of 2008 was $1.1 million as compared to $1.5 million in 2007. The reduction in our revenue was due to the timing of our completing these contracts.

    Research and development costs for the fourth quarter of 2008 were $5.9 million compared to $4.2 million in the fourth quarter of 2007. For the full year, research and development costs increased 38 percent to $24.3 million in 2008 from $17.6 million in 2007. The increases in both the fourth quarter of 2008 and the year ended December 31, 2008 compared to 2007 were due to higher research and development spending to support the Company's strategic focus on creating d
    '/>"/>

    SOURCE Novavax, Inc.
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9

    Related medicine news :

    1. Novavax Announces Release Date of 2007 Fourth Quarter, Full Year Financial Results and Investor Conference Call
    2. Novavax CEO to Present at the Partnering for Global Health Forum
    3. Novavax CEO to Present at Susquehannas Second SIGnificant Options in Healthcare Conference
    4. Novavax Announces Release Date of 2007 Third Quarter Financial Results and Investor Conference Call
    5. Novavax and Allergan Terminate Manufacturing Supply Agreement for Estrasorb
    6. Novavax CEO to Present at the 2007 UBS Global Life Sciences Conference
    7. Cadus Reports 2008 Results
    8. Nephros Reports 2008 Fourth Quarter and Full Year Financial Results
    9. Cardiogenesis Reports Fourth Quarter and Fiscal Year 2008 Results
    10. Tiens Biotech Group (USA) Reports Record Twelve-Month Results
    11. ULURU Inc. Reports Financial Results for Fourth Quarter and Year Ended December 31, 2008
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/23/2014)... 23, 2014 The American Telemedicine ... ATA’s twentieth annual meeting and tradeshow focused exclusively ... to attract over 5,000 attendees and more than ... May 3-5, 2015, in Los Angeles. , ATA’s ... technology professionals from researchers, clinicians, hospital and university ...
    (Date:7/23/2014)... the secrets to better treating the pernicious disorders of ... a paper from American University,s Center for Behavioral Neuroscience. ... obesity with therapies aimed at areas of the brain ... on the hippocampus could play a role in reducing ... therapies and preventive measures often fall short. This is ...
    (Date:7/23/2014)... not be the sole domain of humans, with new ... comes to the love of their master. When ... stuffed dog, the real puppies in the study responded ... researchers from the University of California, San Diego (UCSD). ... attending to the stuffed dog and not when they ...
    (Date:7/23/2014)... research on human cancer genes have been focused on ... to be translated in the form of amino acids ... a regulatory region or activator which controls the expression ... little was known of the role exerted such DNA ... today in Nature in collaboration with the ...
    (Date:7/23/2014)... (PRWEB) July 23, 2014 CarePoint Health ... first hospital in New Jersey to receive the da ... robotics platform in the da Vinci series. This 4th ... profound step forward in innovation. The intuitive da Vinci ... a wide spectrum of minimally invasive and complex surgical ...
    Breaking Medicine News(10 mins):Health News:ATA Seeks Speakers to Present at the World’s Largest Telemedicine, mHealth and Telehealth Conference 2Health News:Targeting the brain to treat obesity 2Health News:Targeting the brain to treat obesity 3Health News:Dogs Can Get Jealous, Too 2Health News:CarePoint Health is First in New Jersey to Receive Newest Surgical Robot Platform 2Health News:CarePoint Health is First in New Jersey to Receive Newest Surgical Robot Platform 3Health News:CarePoint Health is First in New Jersey to Receive Newest Surgical Robot Platform 4
    ... to provide guidance for global market development.SUNNYVALE, Calif. ... Systems, Inc., a technology leader in developing novel ... of Hironori Yamamoto, MD, PhD, of Jichi Medical ... privileged that Dr. Yamamoto has elected to join ...
    ... Other Health Insurers Are Illegally Denying Treatment to Autistic ... being released by Consumer Watchdog: Who: Guillermo Arce , ... father of Frank Nagle , Harvey Rosenfield ... insurance reform initiative, Proposition 103 , Scott Glovsky ...
    ... how autoimmune diseases are triggered , , TUESDAY, Feb. ... by exposure to pig brains might help researchers learn ... More than a year ago, workers at pork processing ... and tingling in their arms and legs. Their common ...
    ... MDVN ) today announced that it will ... on Wednesday, February 25, at 4:30 p.m. Eastern Time ... ongoing Phase 1-2 clinical trial of the Company,s novel ... Scher, M.D., principal investigator of the trial and chief ...
    ... TrinityCare Senior Living, Inc. (formerly OTCBB: JKAN) (the ... facilities, today announced that its Board of Directors has ... the public entity from July 31st to December 31st. ... and re-incorporation was completed and approved on February 16, ...
    ... HARRISBURG, Pa., Feb. 24 Swiss Villa Dairy Farm ... monocytogenes contamination and resumed sales of raw milk on ... milk is milk that has not been pasteurized. ... have samples of their milk laboratory tested due to ...
    Cached Medicine News:Health News:Avantis Medical Systems Announces Key Addition to Scientific Advisory Board 2Health News:Avantis Medical Systems Announces Key Addition to Scientific Advisory Board 3Health News:Avantis Medical Systems Announces Key Addition to Scientific Advisory Board 4Health News:Parents of Autistic Children Fight Back - Warn HMO Regulator Against Changing Rules to Favor Insurers That Deny Access to Medical Treatment 2Health News:Medivation to Host Conference Call and Slide Presentation at 4:30 p.m. EST Wednesday, February 25, to Discuss New MDV3100 Efficacy and Safety Data From Trial in Castration-Resistant Prostate Cancer Patients 2Health News:TrinityCare Senior Living, Inc. Changes Fiscal Year End to December 31st 2
    (Date:7/23/2014)... Research and Markets  has announced the ... Product, End-user & by Lead Type - Global Forecast ... http://photos.prnewswire.com/prnh/20130307/600769 The global ... segments, namely, holter monitor, resting, and stress type diagnostic ... million in 2013 and is poised to grow at ...
    (Date:7/23/2014)... -- RT Oncology Services Corporation today announced that Craig ... directors. Mr. Mundie is currently senior advisor to the ... projects within the company and on technology strategy and ... officer. Mike Martin , president ... a visionary technology executive. His appointment is part of ...
    (Date:7/23/2014)... July 23, 2014  Nonin Medical, Inc., the inventor ... medical monitoring, announced today that Mark VanderWerf , ... elected Chairman of the American Telemedicine Association,s (ATA) Industry ... The ATA is the leading international resource ... technologies. The ATA and its diverse membership work to ...
    Breaking Medicine Technology:Global Diagnostic Electrocardiograph (Resting, Stress, Holter Monitor) (ECG) Market - Forecast to 2020 2Global Diagnostic Electrocardiograph (Resting, Stress, Holter Monitor) (ECG) Market - Forecast to 2020 3Craig Mundie Joins RainTree Oncology Board of Directors 2Craig Mundie Joins RainTree Oncology Board of Directors 3Nonin Medical Announces that Mark VanderWerf has been Elected Chairman of the American Telemedicine Association's Industry Council 2
    ... Transdel Pharmaceuticals, Inc. (OTC Bulletin Board: ... on developing topically administered products using its proprietary transdermal ... exploring strategic alternatives aimed at enhancing shareholder value with ... Advisors, a division of KEMA Partners.  The goal ...
    ... 31, 2011 Nephros, Inc. (OTC Bulletin Board: ... marketing filtration products for therapeutic applications, infection control, and ... Form S-1 for its previously announced rights offering to ... 2011 by the Securities and Exchange Commission. ...
    Cached Medicine Technology:Transdel Pharmaceuticals Announces Exploration of Strategic Alternatives 2Transdel Pharmaceuticals Announces Exploration of Strategic Alternatives 3Nephros Rights Offering Registration Statement Declared Effective 2Nephros Rights Offering Registration Statement Declared Effective 3Nephros Rights Offering Registration Statement Declared Effective 4
    ... manufacturers focus attention on implant design, one ... Profix Total Knee System seeks to establish ... system and the tools to implant them. ... recognized for innovation in total knee instrumentation, ...
    The RT-PLUS Solution is an axially supported rotation knee prosthesis for cemented implantation. The implant is available in three sizes, each of which can be combined with the next size up or down....
    Cementless hip system...
    ... knee system was designed to ... between all articulating surfaces and ... with wear in order to ... with normalized quadriceps and patellar ...
    Medicine Products: